{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T22:34:56Z","timestamp":1795041296690,"version":"4.10.2"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"DOI":"10.1186\/s13195-025-01912-6","type":"journal-article","created":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:01:44Z","timestamp":1763942504000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Higher phosphorylated tau levels predict cognitive decline and amyloid-related imaging abnormalities during lecanemab treatment: clinical practice data"],"prefix":"10.1186","volume":"17","author":[{"given":"Moeko","family":"Noguchi-Shinohara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Yoshinobu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taro","family":"Ozaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiki","family":"Muramatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayano","family":"Shima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Sakashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasutake","family":"Tada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junji","family":"Komatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tokuhei","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenjiro","family":"Ono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,24]]},"reference":[{"key":"1912_CR1","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2212948","volume":"388","author":"CH van Dyck","year":"2023","unstructured":"van Dyck CH, Swanson CJ, Aisen P, Bateman RJ, Chen C, Gee M, et al. Lecanemab in early Alzheimer\u2019s disease. N Engl J Med. 2023;388:9\u201321.","journal-title":"N Engl J Med"},{"key":"1912_CR2","doi-asserted-by":"publisher","first-page":"6259","DOI":"10.1021\/acs.nanolett.3c00187","volume":"23","author":"T Watanabe-Nakayama","year":"2023","unstructured":"Watanabe-Nakayama T, Tsuji M, Umeda K, Oguchi T, Konno H, Noguchi-Shinohara M, et al. Structural dynamics of Amyloid-\u03b2 protofibrils and actions of anti-Amyloid-\u03b2 antibodies as observed by high-speed atomic force microscopy. Nano Lett. 2023;23:6259\u201368.","journal-title":"Nano Lett"},{"key":"1912_CR3","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1002\/ana.27175","volume":"97","author":"M Noguchi-Shinohara","year":"2025","unstructured":"Noguchi-Shinohara M, Shuta K, Murakami H, Mori Y, Komatsu J, Kobayashi C, et al. Lecanemab\u2010associated amyloid\u2010\u03b2 protofibril in cerebrospinal fluid correlates with biomarkers of neurodegeneration in alzheimer\u2019s disease. Ann Neurol. 2025;97:993\u20131006.","journal-title":"Ann Neurol"},{"key":"1912_CR4","doi-asserted-by":"publisher","unstructured":"Ono K, Noguchi-Shinohara M, Watanabe-Nakayama T. The basis of anti-A\u03b2 antibody therapy: the toxicity of A\u03b2 aggregates and the mechanism of action of anti-A\u03b2 antibodies. Intern Med. 2024 Oct;4. https:\/\/doi.org\/10.2169\/internalmedicine.4569-24. Online ahead of print.","DOI":"10.2169\/internalmedicine.4569-24"},{"key":"1912_CR5","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.14283\/jpad.2024.159","volume":"11","author":"LBE Shields","year":"2024","unstructured":"Shields LBE, Hust H, Cooley SD, Cooper GE, Hart RN, Dennis BC, et al. Initial experience with lecanemab and lessons learned in 71 patients in a regional medical center. J Prev Alzheimers Dis. 2024;11:1549\u201362.","journal-title":"J Prev Alzheimers Dis"},{"key":"1912_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-025-01763-1","volume":"17","author":"N Bregman","year":"2025","unstructured":"Bregman N, Nathan T, Shir D, Omer N, Levy MH, David AB, et al. Lecanemab in clinical practice: real-world outcomes in early Alzheimer\u2019s disease. Alzheimers Res Ther. 2025;17:119.","journal-title":"Alzheimers Res Ther"},{"key":"1912_CR7","doi-asserted-by":"crossref","unstructured":"van Dyck C. The Lecanemab Clarity AD Open-Label Extension in Early Alzheimer\u2019s Disease: Initial Findings From the 48 Month Analysis. presented in Alzheimer\u2019s Association International Conference. 2025. https:\/\/www.eisai.co.jp\/ir\/library\/presentations\/pdf\/4523_250731_1.pdf","DOI":"10.1212\/WNL.0000000000216899"},{"key":"1912_CR8","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aaz2387","volume":"6","author":"N Mattsson-Carlgren","year":"2020","unstructured":"Mattsson-Carlgren N, Andersson E, Janelidze S, Ossenkoppele R, Insel P, Strandberg O, et al. A\u03b2 deposition is associated with increases in soluble and phosphorylated tau that precede a positive tau PET in Alzheimer\u2019s disease. Sci Adv. 2020;6:eaaz2387.","journal-title":"Sci Adv"},{"key":"1912_CR9","doi-asserted-by":"publisher","first-page":"905","DOI":"10.3233\/JAD-160651","volume":"55","author":"M Noguchi-Shinohara","year":"2017","unstructured":"Noguchi-Shinohara M, Komatsu J, Samuraki M, Matsunari I, Ikeda T, Sakai K, et al. Cerebral amyloid angiopathy-related microbleeds and cerebrospinal fluid biomarkers in alzheimer\u2019s disease. J Alzheimer\u2019s Dis. 2017;55:905\u201313.","journal-title":"J Alzheimer\u2019s Dis"},{"key":"1912_CR10","doi-asserted-by":"publisher","first-page":"14482","DOI":"10.1073\/pnas.1921327117","volume":"117","author":"SA Cajamarca","year":"2020","unstructured":"Cajamarca SA, Norris EH, van der Weerd L, Strickland S, Ahn HJ. Cerebral amyloid angiopathy-linked \u03b2-amyloid mutations promote cerebral fibrin deposits via increased binding affinity for fibrinogen. Proc Natl Acad Sci USA. 2020;117:14482\u201392.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1912_CR11","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/j.neurobiolaging.2014.10.030","volume":"36","author":"M Cortes-Canteli","year":"2015","unstructured":"Cortes-Canteli M, Mattei L, Richards AT, Norris EH, Strickland S. Fibrin deposited in the Alzheimer\u2019s disease brain promotes neuronal degeneration. Neurobiol Aging. 2015;36:608\u201317.","journal-title":"Neurobiol Aging"},{"key":"1912_CR12","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","volume":"7","author":"MS Albert","year":"2011","unstructured":"Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7:270\u20139.","journal-title":"Alzheimers Dement"},{"key":"1912_CR13","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Kawas CH, et al. The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 2011;7:263\u20139.","journal-title":"Alzheimers Dement"},{"key":"1912_CR14","doi-asserted-by":"publisher","first-page":"351","DOI":"10.2214\/ajr.149.2.351","volume":"149","author":"F Fazekas","year":"1987","unstructured":"Fazekas F, Chawluk JB, Alavi A, Hurtig HI, Zimmerman RA. MR signal abnormalities at 1.5T in Alzheimer\u2019s dementia and normal aging. Am J Roentgenol. 1987;149:351\u20136.","journal-title":"Am J Roentgenol"},{"key":"1912_CR15","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1007\/s12149-022-01769-x","volume":"36","author":"E Imabayashi","year":"2022","unstructured":"Imabayashi E, Tamamura N, Yamaguchi Y, Kamitaka Y, Sakata M, Ishii K. Automated semiquantitative amyloid PET analysis technique without MR images for Alzheimer\u2019s disease. Ann Nucl Med. 2022;36:865\u201375.","journal-title":"Ann Nucl Med"},{"key":"1912_CR16","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-019-0550-8","volume":"11","author":"M Joao Leitao","year":"2019","unstructured":"Joao Leitao M, Silva-Spinola A, Santana I, Olmedo V, Nadal A, Le Bastard N, et al. Clinical validation of the lumipulse G cerebrospinal fluid assays for routine diagnosis of Alzheimer\u2019s disease. Alzheimers Res Ther. 2019;11:91.","journal-title":"Alzheimers Res Ther"},{"key":"1912_CR17","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1111\/cen3.12821","volume":"16","author":"M Noguchi-Shinohara","year":"2024","unstructured":"Noguchi-Shinohara M, Komatsu J, Ono K. Amyloid-related imaging abnormalities in a woman with Apolipoprotein E \u03b54 homozygotes treated with Lecanemab for alzheimer\u2019s disease. Clin Exp Neuroimmunol. 2024;16:254\u20137. https:\/\/doi.org\/10.1111\/cen3.12821.","journal-title":"Clin Exp Neuroimmunol"},{"key":"1912_CR18","doi-asserted-by":"publisher","first-page":"2716","DOI":"10.1093\/brain\/awv181","volume":"138","author":"T Skillb\u00e4ck","year":"2015","unstructured":"Skillb\u00e4ck T, Farahmand BY, Ros\u00e9n C, Mattsson N, N\u00e4gga K, Kilander L, et al. Cerebrospinal fluid Tau and amyloid-\u03b21\u201342 in patients with dementia. Brain. 2015;138:2716\u201331.","journal-title":"Brain"},{"key":"1912_CR19","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000209605","volume":"103","author":"PJ van der Veere","year":"2024","unstructured":"van der Veere PJ, Hoogland J, Visser LNC, Van Harten AC, Rhodius-Meester HF, Sikkes SAM, et al. Predicting cognitive decline in amyloid-positive patients with mild cognitive impairment or mild dementia. Neurology. 2024;103:e209605.","journal-title":"Neurology"},{"key":"1912_CR20","doi-asserted-by":"publisher","first-page":"203","DOI":"10.3233\/ADR-230045","volume":"8","author":"MJ Garcia","year":"2024","unstructured":"Garcia MJ, Leadley R, Ross J, Bozeat S, Redhead G, Hansson O, et al. Prognostic and predictive factors in early Alzheimer\u2019s disease: a systematic review. J Alzheimers Dis Rep. 2024;8:203\u201340.","journal-title":"J Alzheimers Dis Rep"},{"key":"1912_CR21","doi-asserted-by":"publisher","first-page":"5143","DOI":"10.1002\/alz.13859","volume":"20","author":"CR Jack","year":"2024","unstructured":"Jack CR, Andrews JS, Beach TG, Buracchio T, Dunn B, Graf A, et al. Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Alzheimer\u2019s association workgroup. Alzheimers Dement. 2024;20:5143\u201369.","journal-title":"Alzheimers Dement"},{"key":"1912_CR22","doi-asserted-by":"publisher","first-page":"e877","DOI":"10.1212\/WNL.0000000000005060","volume":"90","author":"E Liu","year":"2018","unstructured":"Liu E, Wang D, Sperling R, Salloway S, Fox NC, Blennow K, et al. Biomarker pattern of ARIA-E participants in phase 3 randomized clinical trials with bapineuzumab. Neurology. 2018;90:e877-86.","journal-title":"Neurology"},{"key":"1912_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25147543","volume":"25","author":"J Doroszkiewicz","year":"2024","unstructured":"Doroszkiewicz J, Kulczy\u0144ska-Przybik A, Dulewicz M, Mroczko J, Borawska R, S\u0142owik A, et al. Associations between microglia and astrocytic proteins and tau biomarkers across the continuum of Alzheimer\u2019s disease. Int J Mol Sci. 2024;25:7543.","journal-title":"Int J Mol Sci"},{"key":"1912_CR24","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/alz.13450","volume":"20","author":"W Pelkmans","year":"2024","unstructured":"Pelkmans W, Shekari M, Brugulat-Serrat A, S\u00e1nchez-Benavides G, Minguill\u00f3n C, Fauria K, et al. Astrocyte biomarkers GFAP and YKL-40 mediate early Alzheimer\u2019s disease progression. Alzheimers Dement. 2024;20:483\u201393.","journal-title":"Alzheimers Dement"},{"key":"1912_CR25","doi-asserted-by":"publisher","first-page":"4414","DOI":"10.1093\/brain\/awad188","volume":"146","author":"H Hampel","year":"2023","unstructured":"Hampel H, Elhage A, Cho M, Apostolova LG, Nicoll JAR, Atri A. Amyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristics. Brain. 2023;146:4414\u201324.","journal-title":"Brain"},{"key":"1912_CR26","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1001\/jamaneurol.2025.0065","volume":"82","author":"JA Zimmer","year":"2025","unstructured":"Zimmer JA, Ardayfio P, Wang H, Khanna R, Evans CD, Lu M, et al. Amyloid-related imaging abnormalities with Donanemab in early symptomatic alzheimer disease: secondary analysis of the TRAILBLAZER-ALZ and ALZ 2 randomized clinical trials. JAMA Neurol. 2025;82:461\u20139.","journal-title":"JAMA Neurol"},{"key":"1912_CR27","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.3174\/ajnr.A3500","volume":"34","author":"J Barakos","year":"2013","unstructured":"Barakos J, Sperling R, Salloway S, Jack C, Gass A, Fiebach JB, et al. MR imaging features of amyloid-related imaging abnormalities. AJNR Am J Neuroradiol. 2013;34:1958\u201365.","journal-title":"AJNR Am J Neuroradiol"},{"key":"1912_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.tjpad.2025.100160","volume":"12","author":"C Chen","year":"2025","unstructured":"Chen C, Katayama S, Lee JH, Lee JY, Nakagawa M, Torii K, et al. Clarity AD: Asian regional analysis of a phase III trial of Lecanemab in early alzheimer\u2019s disease. J Prev Alzheimers Dis. 2025;12:100160.","journal-title":"J Prev Alzheimers Dis"},{"key":"1912_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25116180","volume":"25","author":"A Singh","year":"2024","unstructured":"Singh A, Bhatt KS, Nguyen HC, Frisbee JC, Singh KK. Endothelial-to-mesenchymal transition in cardiovascular pathophysiology. Int J Mol Sci. 2024;25:6180.","journal-title":"Int J Mol Sci"},{"key":"1912_CR30","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/S0022-510X(02)00289-7","volume":"203\u2013204","author":"B Borroni","year":"2002","unstructured":"Borroni B, Akkawi N, Martini G, Colciaghi F, Prometti P, Rozzini L, et al. Microvascular damage and platelet abnormalities in early alzheimer\u2019s disease. J Neurol Sci. 2002;203\u2013204:189\u201393.","journal-title":"J Neurol Sci"},{"key":"1912_CR31","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s12603-010-0043-8","volume":"14","author":"BB Yavuz","year":"2010","unstructured":"Yavuz BB, Dede DS, Yavuz B, Cankurtaran M, Halil M, Ulger Z, et al. Potential biomarkers for vascular damage in Alzheimer\u2019s disease: thrombomodulin and von Willebrand factor. J Nutr Health Aging. 2010;14:439\u201341.","journal-title":"J Nutr Health Aging"},{"key":"1912_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.ceb.2025.102528","volume":"95","author":"M Casquero-Veiga","year":"2025","unstructured":"Casquero-Veiga M, Ceron C, Cortes-Canteli M. Alzheimer\u2019s disease and vascular biology \u2013 a focus on the procoagulant state. Curr Opin Cell Biol. 2025;95:102528.","journal-title":"Curr Opin Cell Biol"},{"key":"1912_CR33","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1001\/jamaneurol.2024.3770","volume":"81","author":"B Dubois","year":"2024","unstructured":"Dubois B, Villain N, Schneider L, Fox N, Cambell N, Galasko D, et al. Alzheimer disease is a clinical-biological construct: an IWG recommendation. JAMA Neurol. 2024;81:1304\u201311.","journal-title":"JAMA Neurol"},{"key":"1912_CR34","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1017\/S1041610214000416","volume":"8","author":"L Velayudhan","year":"2014","unstructured":"Velayudhan L, Ryu SH, Raczek M, Philpot M, Lindesay J, Critchfield M, et al. Review of brief cognitive tests for patients with suspected dementia. Int Psychogeriatr. 2014;8:1247\u201362.","journal-title":"Int Psychogeriatr"}],"updated-by":[{"DOI":"10.1186\/s13195-026-02196-0","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T00:00:00Z","timestamp":1790380800000}}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-025-01912-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-025-01912-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-025-01912-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T22:02:11Z","timestamp":1790546531000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13195-025-01912-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,24]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1912"],"URL":"https:\/\/doi.org\/10.1186\/s13195-025-01912-6","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,24]]},"assertion":[{"value":"22 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original article has been updated: Typographical errors in Table 3 were corrected.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2026","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s13195-026-02196-0","URL":"https:\/\/doi.org\/10.1186\/s13195-026-02196-0","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Medical Ethics Review Board of Kanazawa University (approval number 114625). Written informed consent was obtained from all patients who visited after the study protocol was approved by the Medical Ethics Review Board of Kanazawa University. For patients who visited before that, consent was obtained by opt-out on the website.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This manuscript does not contain any individual person\u2019s data in any form.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"T.Y., T.O., D.M., A.S., Y.S., Y.T., H.Y., J.K., and T.I. have nothing to report. M. N\u2012S. and K.O. report receiving honoraria from Eisai.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"251"}}